Daewon Pharmaceutical Co (003220) Fair Value & Analysis
Healthcare · KR · Market cap 164B KRW
Fair value as of: Jul 22, 2026
From 14 valuation models · updated today
Fair value updated Jul 22, 2026, revised from 55,830 KRW to 10,761 KRW (−80.7%) since Jun 25, 2026. Share price −9.6% over the past month.
Price vs Fair Value (12 months)
12‑month range 7,300 KRW – 13,321 KRW · fair‑value band 6,311 KRW – 15,212 KRW · the 7,720 KRW price screens below the 10,761 KRW fair value. As of Jul 22, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Daewon Pharmaceutical Co (003220) currently trades at 7,720 KRW, while our model-based Fair Value estimate is 10,761 KRW, implying the stock looks roughly 39.4% undervalued today. We read business quality at 37/100 (below-average quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium), always confirm before acting.
Over the trailing twelve months, Daewon Pharmaceutical Co generated revenue of 606B KRW at a net margin of -0.7%. Revenue grew 0.1% year over year. It earns a return on equity of -1.8%. Net debt stands at 151B KRW. Fundamentals as of Jul 22, 2026
Our scenario range runs from 6,311 KRW (bear case) to 15,212 KRW (bull case); at 7,720 KRW, the current price sits within that range. The share trades about 44% below its 52-week high, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -43% fair-value upside, at 39%, 003220 screens cheaper than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 22, 2026. TTM = trailing twelve months.
About the company
Daewon Pharmaceutical Co., Ltd., a pharmaceutical company, manufactures and sells medicines and medical supplies in South Korea. It offers various medicines for circulatory, respiratory, antibiotic, chemotherapy, and psychoneurosis use. The company's principal products include Oramin-F Soft Cap, a multivitamin product; Pelubi Tablet, a NSAID product for pain relief; Freefol-MCT Inj., a microemulsion propofol for the anti-exogenous infectious bacteria; Megex-I Susp, a medicine that supplements subalimentation of cancer patients; Trigel Susp, a therapy for gastritis and duodenal ulcer; and Renamezin Cap, a spherical carbonaceous adsorbent for chronic kidney disease. It also exports its products to approximately 40 countries primarily in Asia, Central and South America, the Middle East, CIS, and Africa. The company was founded in 1958 and is headquartered in Seoul, South Korea.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Daewon Pharmaceutical Co reported revenue of 605B KRW in FY2025 versus 354B KRW in FY2021, a compound +14.3%/yr. Reported net income was −1.4B KRW in FY2025.
Is 003220 fairly valued? → Check now
Similar stocks
10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jul 22, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Jiangsu Hengrui Pharmaceuticals Co 600276 | ¥47.01 | ¥26.59 | -43% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,786 | ₹991.46 | -44% |
| Hansoh Pharmaceutical Group 3692 | HK$29.30 | HK$23.90 | -18% |
| Divi's Laboratories Limited DIVISLAB | ₹6,623 | ₹1,461 | -78% |
| Torrent Pharmaceuticals Limited TORNTPHARM | ₹4,464 | ₹1,504 | -66% |
| PharmaEssentia Corporation 6446 | 934.00 TWD | 365.87 TWD | -61% |
| Cipla Limited CIPLA | ₹1,416 | ₹1,466 | +4% |
| Zydus Lifesciences Limited ZYDUSLIFE | ₹1,112 | ₹697.22 | -37% |
| Lupin Limited LUPIN | ₹2,340 | ₹2,477 | +6% |
| Mankind Pharma Limited MANKIND | ₹2,538 | ₹1,161 | -54% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Daewon Pharmaceutical Co (003220) undervalued?
What is the fair value of 003220?
What is the quality score of 003220?
What is the revenue of Daewon Pharmaceutical Co (003220)?
What is the net profit margin of 003220?
Does Daewon Pharmaceutical Co pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Unlock the full Daewon Pharmaceutical Co analysis, and try Pro free
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.